1 hereditary periodic fever syndromes a group of inherited disorders characterized by recurrent,...

1

Hereditary Periodic Fever Syndromes A group of inherited disorders characterized by recurrent, self-limited episodes of fever and synovial, serosal, and/or oculocutaneous inflammation. 169 Claudius Galen 1790 Heberden 1895 Osler 1908 Janeway & Mosenthal 1940 Kile & Rusk 1945 Siegal 1949 Reimann 1958 Heller 1962 Muckle & Wells 1981 Prieur, Griscelli 1982 Williamson et al 1984 van der Meer et al

2

Differential Diagnosis of Periodic Fevers

FMF HIDS TRAPS (FHF) MWS/FCU/CINCAGenetics MEFV MVK TNFRSF1A CIAS1/NALP3 (16p13) (12q24) (12p13) (1q44) Protein Pyrin/Mnstrn Mevalonate TNF receptor 1 NALP3/

kinase cryoppyrin Onset < 20 Childhood May remit/ 95% <5 years

relapse

Fever Abrupt Fast on, Variable, 24 hours on + off slow off less in adults

Duration 1- 4 days 3 - 7 days Up to weeks 1- 2 days

Nodes Rare Cervical Common No nodes ++

Rash Rare; legs 90%(pleiomorphic) All over (erysipelas) Maculo-papular

Oedema Very rare No Peri-orbital No

Amyloid Common None 25% 25%

Therapy Colchicine Etanercept? Etanercept Anakinra

3

CARD

CARDPyrin

Pyrin

ASC can act as a Link between Pyrin and Apoptotic pathways

PYRIN

ASC

NALP1

4

Amyloidosis of the kidney

5

A heterogenous group of inherited disorders characterised by spontaneous attacks of systemic inflammation without apparent autoimmune basis

• No demonstrable source of infection as precipitating cause

• Absence of high-titre autoantibodies and antigen specific autoreactive T cells

• No evidence of auto-antigenic exposure

Autoinflammatory Syndromes

6

Autoinflammatory Syndromes and related disorders

Hereditary periodic fevers

Gene/chromosome Protein FMF MEFV (16p13) Pyrin/marenostrin HIDS MVK (12q24) Mevalonate kinase TRAPS (FHF) TNFRSF1A (12p13) TNF Receptor 1 FCU/FCAS NALP3/CIAS1/PYPAF1 (1q44) NALP3/Cryopyrin/PYPAF1 MWS/FCAS NALP3/CIAS1/PYPAF1 (1q44) NALP3/Cryopyrin/PYPAF1 CINCA/NOMID NALP3/CIAS1/PYPAF1 (1q44) NALP3/Cryopyrin/PYPAF1 PAPA PSTPIP1/CD2BP1 (15q24) CD2-binding protein 1

Granulomatous disorders

Crohn’s (IBD) NOD2 (16q12) Nucleotide binding oligomerization domain

Blau Snydrome NOD2 (16q12) Nucleotide binding oligomerization domain

7

sTNF/sTNFR

mTNFRSF1A(mTNFR1)

Disulphide bondsDisulphide bonds

8

TNFRSF1A

DD

trimerise

DD

DD

DD

DD

DD

DD

RIP

1

TRADD

DD

TR

AF

2

DD

RIP

1

TRADD

DD

TR

AF

2Complex I

NF-Bactivation

DD

DD

DDModification/

dissociation

DD

RIP

1

TRADD

DD

TR

AF

2

DD

RIP

1

TRADD

DD

TR

AF

2

Recruitment of FADD and caspase-8/10

Complex II

Apoptosis

DISC

FADD

DD

TR

AD

D

DD

DD

TR

AD

D

DDTRAF2

TRAF2

RIP1

RIP1DDDED

DDDEDCASP-8/10

TNF

c-FLIP

Micheau et al. Cell 114, 1810190, 2003Micheau et al. Cell 114, 1810190, 2003

9

Two views of the six helical Death Domain-FoldMotifs

Death domains

Caspase activation and recruitment domains (CARDs)

Pyrin domains

Adaptor domain architecture important in homotypic protein- protein interactions

Protein Science 10:1911, 2001

Death effector domains

10

The conserved pyrin domain defines a family of apoptotic/inflammatory proteins

CARDCARD

B SPRY

ASC/CARD5

NACHTNACHT

NACHTNACHT LRRLRR

NACHTNACHTPYD??????

B30.2B30.2

NALP3/CIAS1/PYPAF1

LRRLRR

NOD2/CARD15

PYD

NALP1/ CARD7

PYD

PYD

PYRIN/MARENOSTRIN

LRRLRR

CARDCARD

CARDCARD CARDCARD

11

PYD is a flexibly disordered loop instead of 3 (NALP1)

12

MRI showing fronto-parietal subcortical lesions in TRAPS patientMRI showing fronto-parietal subcortical lesions in TRAPS patient

13

FAMILY A

I

1

1

1 2

2

2

3

3

3

4

4

4 65

5 7

7

8

8

9

9

10

10

11 12 13

A BC

D

FAMILY B

IV

I

possibly affected.

FAMILY C

affected.

III

II

I

II

III

IV

I

III

II

IV

Familial Hibernian Fever families

6

14

Location and genomic structure of TNFRSF1A gene- chromosome 12p13

Exons 1 2 3 4 5 6 7 8 9 10

Signal Peptide Extracellular Transmembrane Intracellular

3’UTR

ptercen

C1 S/R TNFRSF1ACD4 CD9 VWFDRPLA

0.09 0.02 0.002 0.12

15

DNA Sequence Electropherograms Showing Disease-Associated TNFRSF1A MutationsDNA Sequence Electropherograms Showing Disease-Associated TNFRSF1A Mutations

16

Missense Mutations in the TNFRSF1A Extracellular Domains

Mutation Exon Amino Acid Ethnic Background

175 TC 2 Cys30Arg Irish

185 GA 2 Cys33Tyr Irish/Scottish

236 CT 3 Thr50Met Irish

French-Canadian

242 GT 3 Cys52Phe Irish/English/German

349 TC 4 Cys88Arg Scottish (Australian)

350 GA 4 Cys88Tyr Finnish

17

2) constitutive activation, formation of intermolecular disulfide bonds between unpaired cysteines in mutant receptors (Santoro, 1995) -Il-6 induction - crude test - normal

3) resistance of mutant TNFRSF1A to the normal homeostatic effects of activation-induced cleavage

.

- FACS analysis - reduced/delayed TNFRSF1A shedding in affected members of family with C52F mutation

1) increased affinity of mutant TNFRSF1A for ligand (i.e TNF) -binding and affinity studies - normal

.

Possible Disease Mechanisms in TRAPS

18

Periodic fever family with amyloidosis of kidney

affected

unaffected

19

TNF Receptors on Leukocytes from Patients with the C52F MutationTNF Receptors on Leukocytes from Patients with the C52F Mutation

20

Leukocytes Bearing the C52F Mutation Have Defective Clearance of TNFRSF1A (CD120a)Leukocytes Bearing the C52F Mutation Have Defective Clearance of TNFRSF1A (CD120a)

21

“TRAPS”

TNF Receptor-Associated Periodic Syndrome

22

IL-1

Haem A Ubiquinone

Endothelial cellICAM1, ELAM

Lymph node organogenesis

TNF

Acute phase response (Il-6, SAA, CRP)

Overproduction Septic shock

Hepatic failure Vasculitis Encephalitis Cardiac cachexia

Dolichol

HypothalmusFever/Sleep

T cell activation Il-6

B cell activation

Ig production

Cellular activation

(Cardiac, hepatic, bone, etc)matrix metalloproteinase (stromelysin), plasmin and collagenase production

Breaches anti-protease barrier

TISSUE DESTRUCTION

Virus/endothelium

Macrophage activation

23

IK K

IK K

NE MO

S ignal osome

m TNF TACE

SODD

MAP kinase

NF B tr anscri ption

Su rvi val - Anti -apo ptot ic

pr otein s

FADD

TRADD

CASPASE-8 RA IDD

RIP

FLIP

sTNF /

sTNF R

?Shedd ase

NFkB

TRAF2RIP

TRADD

S ign al pr eventi on

sTNF /

sTNF R

TNF RSF 1A

(TN FR 1)

BID/BI M

Bax Bak

BA X

Bcl2 Bclx

Cytochrome c release, Apaf1 activation of downstream caspases e.g 3, 6 and 7

***Death - apoptosis

Extrinsic death receptors

Intrinsic Plasma membraneEndoplasmic reticulum

CytosolNucleus

Anti-apoptotic Bcl2, Bclxl, Bclw, Mcl1

Pro-apoptotic (multi-domain) Bax, Bakl, Bok/Mtd

Pro-apoptotic (BH3 domain only)Bid, Bad, Blk, Bim/Bod, Nix, Noxa

24

SCREENING METHODS for TRAPSSCREENING METHODS for TRAPS Genotyping: microsatellites within (TNFRp55)

and flanking (D12S99 and D12S77)TNFRSF1A locus used to genotype family members.

DHPLC: we screened 20 ADRF families and 184 sporadic cases forTNFRSF1A mutations using the Transgenomic WAVE® System.

Sequencing: ABI 373A sequencer.

ELISA assays: used to determine serum levels of TNFRSF1A and TNFRSF1B (sTNFRSF1A and sTNFRSF1B).

25

DHPLC elution profileDHPLC elution profile

0.0

1.5

3.0

. 1. 2. 3. 4. 5. 6. 7. 8. 9.

Time (min)

0.0

2.5

. 1. 2. 3. 4. 5. 6. 7. 8. 9.

Time (min)

Wt C70R

26

a b05 0903 0708 13

MARKERSD12S99TNFRp55D12S77

a d05 0403 0708 12

a d05 0403 0708 12

c d04 0407 0708 12

a c05 0403 0708 08

21

3

831

875 326

Israeli Arab family A

612

1114

Periodic fever

C70R M 1 2 3 4 5 C

500

800

Not genotyped

4 5

De-novo C70R mutation (Israeli Arab family)

27

II

IV

III

I

c d04 04A A06 0606 11

e f04 08G G02 0211 12

a e04 04G G02 0205 11

a e/f04 04G G02 0205 12*

d g04 06-- --06 0111 10

d b04 04A A06 0711 11

c j04 01A A06 0706 11

c j04 01A A06 0706 11

826 731

g h 04 04 G A 06 01 06 03

a c04 04G A02 0605 06

Order of markers D12S99 +36 A/G TNFRp55 D12S77

Irish Family

727

781 11401450

1450

650

650

Soluble TNFRSF1A levels n= 746-1966pg/ml

Periodic fever in an Irish Family - unlinked to all known HPF loci

28

7 8 9 10 11 12 13 14 S2

sTN

FR

SF

1A

(p

g/m

l)

s TNFRSF1A levels in affected family members of

(A) TRAPS (B) families without mutation s TNFRSF1A levels in affected family members of

(A) TRAPS (B) families without mutation

(A)

(B)

746

1966

746

1966

unaffected

Periodic fever

Probably affected

29

A total of 8 novel TNFRSF1A mutations (T37I, D42, G46E, T50K, F60L,C70R, C70S and R92P), and 5 known (c.193-14 G>A, P46L, T50M, C88R,

and R92Q) mutations in a study of 20 families. The C70S mutation found in a Japanese patient

Affected members in 4 of the 7 families without TNFRSF1A mutations have low sTNFRSF1A

These findings indicate the presence of genetic heterogeneity in ADRFs.

Summary of TRAPS and ADRF families

30

Etanercept (a recombinant p75 TNFR:Fc fusion protein), in TRAPS: the Promise of Molecular MedicineEtanercept (a recombinant p75 TNFR:Fc fusion protein), in TRAPS: the Promise of Molecular Medicine

Patient 3 (14yo, M, H22Y)

0

10

20

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 3 (14yo, M, H22Y)

0

10

20

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 4 (32yo, M, T50M)

0

20

40

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 4 (32yo, M, T50M)

0

20

40

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 2 (15yo, F, T50M)

0

30

60

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 2 (15yo, F, T50M)

0

30

60

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 1 (50yo, M, T50M)

0

25

50

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

Patient 1 (50yo, M, T50M)

0

25

50

Q1 Q2 Q3 Q4

Study Phase

Att

ack

Sco

re

31

Apoptosis -

A type of programmed cell death in which the cell dies (commits suicide) through a series of cellular events including enzymatic fragmentation of DNA.

# necrosis - cells bursts and discharges contents. e.g. infarction

32

Pyrin/marenostin is mainly expressed in leucocytesPyrin/marenostin is mainly expressed in leucocytes

Cell 90; 797, 1997

33

Pyrin Interaction with ASC proteinPyrin Interaction with ASC protein

Apoptosis-Associated speck-like protein with a caspase recruitment domain(CARD)

Interacts with pyrintwo-hybrid, IP, andfluorescence microscopy

Aggregates during Apoptosis in HL-60 cells

Proapoptotic

Interacts with pyrin by yeasttwo-hybrid, IP, andfluorescence microscopy

Proapoptotic

N-terminal pyrin domain, C- terminal CARD

GFP-pyrin + ASC-myc(Cy3 label) merged

34

Monocytes from Pyrin Truncation MiceManifest a Defect in ApoptosisMonocytes from Pyrin Truncation MiceManifest a Defect in Apoptosis

24 hr 48 hr 72 hr

+/+ -/- +/+ -/- +/+ -/-

35

Connecting Pathways with Patients: Mutations in a Pyrin-Binding Protein Cause PAPA Syndrome

*

E250Q

Pyrin

B CC B30.2Pyrin domain

1 781

CC SH31 415

PSTPIP1/CD2P1

*A230T

PAPA Syndrome: Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne

36

Autosomal dominant disorders of unknown cause, variably associated with arthralgias, rashes and conjunctivitis

FCAS (also Familial cold urticaria (FCU)

cold induced fever (24-hour) and rash

Muckle-Wells syndrome (MWS)

sensorineural deafness, amyloidosis

Familial cold autoinflammatory Syndrome (FCAS)/Muckle Wells

37

North-Indian familyNorth-Indian family

periodic fever with amyloidosis periodic fever without amyloidosis

a c01 0804 0103 0101 0101 0402 0403 04

d b01 0801 0211 0602 0801 0104 0102 02

e f 01 0802 0100 0001 0501 0403 0504 02

I

II

III

d b01 0101 0211 0602 0801 0104 0102 02

a d01 0104 0103 1101 0201 01-- --03 02

d b01 0104 0211 0602 0801 0104 0102 02

c b01 0801 0401 0601 0804 0104 0104 02

b n01 0901 0406 0308 0201 0101 0302 03

b m01 0901 0106 0408 0201 0101 0202 03

d l01 0804 0211 1102 0201 0104 0502 02

a k01 0104 0203 0201 0501 0102 0103 04

b i-- --02 0106 1108 0501 0401 0502 02

b j01 0102 0206 1108 0701 0101 0602 02

c f08 0804 0101 0601 0504 0104 0304 04

d h01 0101 0111 0202 0201 0104 0202 02

c g 01 01 01 04 01 01 01 02 04 04 04 04 04 02

a c08 0104 0403 0101 0101 0402 0403 04

a d01 0104 0403 1101 0201 0102 0403 02

c p 01 01 04 02 01 03 01 07 04 04 04 06 04 02

38

The conserved pyrin domain defines a family of apoptotic/inflammatory proteins

CARDCARD

B SPRY

ASC/CARD5

NACHTNACHT

NACHTNACHT LRRLRR

NACHTNACHTPYD??????

B30.2B30.2

NALP3/CIAS1

LRRLRR

NOD2/CARD15

PYD

NALP1/ CARD7

PYD

PYD

PYRIN/MARENOSTRIN

LRRLRR

CARDCARD

CARDCARD CARDCARD

periodic fever with amyloidosis

periodic fever without amyloidosis

I

II

III

M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

2 6

11

1083 4 5

2019181715141312 16

97

1

4 51

7

3 6

8

2

M 1 2 3 4 5 6 7 8

I

I I

III

IV

A

B

Cold sensitivity/periodic fever without amyloidosis

40

NACHT

V198MV198M

Q306LQ306L

D303ND303N

A352VA352V

A439TA439T

E627GE627G

R260WR260W

A439VA439V

G569RG569R

F573SF573S

FCU/FCAS mutations Mutations found in more than one disease

CINCA mutationsMWS mutations

L305PL305P

F309SF309S

H358RH358R

T436NT436N

M662TM662T

LRRPYRIN

T348MT348M V351MV351M

A374NA374N

F523LF523L

Y570CY570C

Motif III, Motif III, MgMg++

L264HL264H

L353PL353P

R488KR488K

NALP3/CIAS1/PYPAF1 mutations MWS,FCU/FCAS, CINCA/NOMIDNALP3/CIAS1/PYPAF1 mutations MWS,FCU/FCAS, CINCA/NOMID

41

CARD

CARD P20 P10

ASC

IL-1-processing

NF-kB modulationInflammation with Fever

Caspase-1

Pyrin

Cryopyrin/NALP3Pyrin/marenostrin

PYDB box

CCB30.2

Apoptosis

LRR

PYD

NACHT

PYD

The assembly of cryopyrin/NALP3/PYPAF1 and pyrin/marenostrin with ASCThe assembly of cryopyrin/NALP3/PYPAF1 and pyrin/marenostrin with ASC

42

IL-1 receptor antagonist (Kineret) therapy in FCU patient (100 mg daily subcutaneously)IL-1 receptor antagonist (Kineret) therapy in FCU patient (100 mg daily subcutaneously)

North Indian Patient

Mar01 Jan02 Dec02

1

10

100

1000

Seru

m S

AA

mg

/l

43

Mechanisms - related to NFkB activation and ?defective apoptosis in FMF, TRAPS and MWS. HIDS?.

Proinflammatory polymorphisms TNFRSF1A - P46L, R92Q. NALP3 - V198M (V200M)

MEFV - E148Q (amyloidosis)

Modifier Genes e.g MICA in FMF susceptibility Behçets increases penetrance MEFV mutations.

SAA1a/a in FMF patients with amyloidosis.

Polygenic nature of all “Mendelian diseases”?

Genetic heterogeneity and reduced penetrance.

Developing Concepts

44

Acetyl CoA

Acetyl CoA + Acetoacetyl CoA

HMG CoA

Mevalonate

Mevalonate-P

Mevalonate-PP

Isopentenyl-PP Isopentenyl-Adenine

Geranyl-PP

Farnesyl-PP

Squalene

Cholesterol

Plasma LDL

Dolichol

Haem A Ubiquinone

Farnesylated Proteins (Ras, lamin B, etc

Vitamin D

Bile Acids

Steroid Hormones

Lipoproteins LDL receptor

kinase Defect in HIDS

reductase

synthase Cholesterol Metabolism and Isoprenoid Biosynthesis

45

46

Exon: 1 2 3 4 5 6 7 8 9 10 11

Organisation of the MVK gene and location of mutations leading to the HIDS/MA phenotype

= 2bp deletion

= Nonsense mutation

= Mevalonic Aciduria

= HIDS

= Mevalonic Aciduria

= Missense mutation